[at noodls] – 6-Month (Stage 1) Results from Ongoing Phase 3 Fabry Disease Monotherapy Study at Lysosomal Storage Disease Network WORLD Symposium (LDN WORLD) in February 2013; 12-Month Results Expected in 2Q13 Pompe, … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboardSee who Amicus is hiring next, click here to view […]
[at noodls] – Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease Results to be Presented at LDN WORLD Symposium in … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboardSee who Amicus is hiring next, click here to view […]
[at noodls] – CRANBURY, N.J., Jan. 2, 2013 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboardSee who Amicus is hiring next, click here to view […]
[at noodls] – CRANBURY, N.J. and LONDON, Dec. 19, 2012 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD) and GlaxoSmithKline plc (GSK) today announced the 6-month primary treatment period results from the first … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboardSee who Amicus is hiring next, click here to view […]
[at noodls] – Amicus Therapeutics Announces Additional Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease Drug-Drug Interaction Study Evaluating Pharmacokinetics … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – CRANBURY, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced a … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Amicus Therapeutics Announces Third Quarter 2012 Financial Results & Corporate Updates 6-Month Results Expected 4Q12 and 12-Month Results Anticipated 1H13 From Phase 3 Fabry Monotherapy Study 011 Additional … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Amicus Therapeutics Announces Updated Results From Phase 2 Extension Study of Migalastat HCl for Fabry Disease Kidney Interstitial Capillary GL-3 Results for 60-Week Treatment on Migalastat HCl Presented … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – CRANBURY, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced a … moreView todays social media effects on FOLDView the latest stocks trending across Twitter. Click to view dashboard […]
